HopeStage
Back to all studies
CompletedNCT00202293

Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features

Medication studyAges 15–29AustraliaBipolarity
The study in practice

Understand this study

Who was this study for?

Listed age limits: 15 years to 29 years.

Listed locations
ParkvilleSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateOctober 1, 2001
Recruitment status
Completed
Enrollment listed in the registry
83
Sponsor
Melbourne Health
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Australia
Age range
From 15 Years to 29 Years
Official registry ID
NCT00202293
Official title
Show the full official title

Comparison of Combination Olanzapine and Lithium and Combination Chlorpromazine and Lithium in the Treatment of a First Manic Episode With Psychotic Features.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Parkville

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Melbourne Health.

Did this study involve medication?

Yes. The study involved medication, including Olanzapine, lithium and Chlorpromazine.

Who was this study for?

Listed age limits: 15 years to 29 years.

Want to explore more studies?

Explore studies